After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR /KEYNOTE-581 trial
Final results will be presented at ASCO 2023. | May 25, 2023
25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, .
Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.
Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers-;even in microscopic amounts.